The PM Society’s ‘Is Pharma Marketing built on Straw, Sticks, or Bricks?’ interactive information afternoon, held at The Royal Society of Medicine in London late last year, set out to bring
Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic form of dementia from UK biotech AviadoBio for around $50 million.
